Lung Cancer Metastatic
Conditions
Keywords
non small cell lung cancer, oligoprogression, steretactic body radiotherapy
Brief summary
A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.
Interventions
RADIATIONSABR
SABR to all oligoprogressive lesions + continuation of current systemic therapy
OTHERStandard of care
Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
Sponsors
Centre hospitalier de l'Université de Montréal (CHUM)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Intervention model description
Randomized screening phase II trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years * Metastatic NSCLC enrolled in our CRCHUM Lung Cancer Registry and co-enrolled to the PERa registry * Ability to provide written informed consent * Eastern Cooperative Oncology Group (ECOG) performance status 0-3 * Oligoprogression to 1-5 extracranial lesions ≤ 5cm and involving ≤ 3 organs. Progression at the primary tumor site should be counted within the total of 5 lesions. For patients with lymph node metastases, each node is counted as one site of metastasis. * Oligoprogression while on ICI or TKI (any line) * Patients with brain metastasis are allowed; brain metastasis are not counted in the maximum number of lesions and should be treated as per standard of care * All sites of disease can, in the opinion of the investigator, be safely treated and targetable with SABR (taking into account prior local therapy, organ function and underlying medical condition such as inflammatory bowel disease, pulmonary fibrosis, etc.) * Patients with prior metastases that have been treated with ablative therapies (e.g. radiotherapy, surgery or radiofrequency ablation) before their current line of systemic therapy, are eligible.
Exclusion criteria
* Any lesion beyond 5 cm * Pregnancy or breastfeeding * Any medical condition that could, in the opinion of the investigator, preclude radiotherapy or prevent follow-up after radiotherapy. * Presence of spinal cord compression Metastatic disease that invades the GI tract (including esophagus, stomach, small or large bowel)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 5 years | PFS defined from randomization to disease progression at any site or death |
| OS | 5 years | OS defined as time from randomization to time of death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life Measured using the FACT-G tool, lung cancer-related patient reported outcome- CTCAE (PRO-CTCAE) | 5 years | Measured using the FACT-G tool, lung cancer-related patient reported outcome- CTCAE (PRO-CTCAE) |
| Quality of life 5-level EQ-5D (EQ-5D-5L) | 5 years | questionnaire |
| Grade ≥ 3 toxicity | 5 years | Measured using the Common Terminology Criteria for Adverse Events (CTCAE v5.0) |
| Local control | 5 years | Defined as time from the end of SABR treatment to date of local failure and will be measured only in the experimental arm |
| Time to next systemic therapy | 5 years | Defined as time from randomization to time of subsequent therapy line |
Countries
Canada
Contacts
STUDY_CHAIRHouda Bahig, MD PhD
Centre hospitalier de l'Université de Montréal (CHUM)
STUDY_CHAIRBertrand Routy, MD PhD
Centre hospitalier de l'Université de Montréal (CHUM)
Outcome results
None listed